Terrorismo Sanitario y gripe

Cómo por arte de magia, y con ganas de no quedarse con más vacunas que de hacer algo de prevención real, el Ministerio de Salud informa sobre 8 muertos los ultimos dias por gripe A, supongo se refieren al A/N1H1 California 7, el mismo de la pandemia.
Este blog está lleno de artículos sobre mi opinión durante la pandemia. Y si estos datos son reales, Entonces de 3600 o 4000 casos por año de muertos ..CON GRIPE ( nadie se muere de la gripe ), o sea un caso cada 20 dias, llevamos un otoño dónde apenas se puede contar menos de un caso por dia.
Por si alguno se olvidó, en el mundo se decia que habia 250 a 500 mil muertes anuales, con la gripe vieja. Y durante el año de la pandemia (2009) murieron en todo el mundo aproximadamente unas 18.500 personas por el N1H1. En la Argentina frente a esos 3600 aproximadamente, sólo murieron 615 personas, cuando el virus predominaba en adultos en un 90% y en niños en un 99%. Es decir 6 veces más benigno.
 Se acuerdan que iba a mutar ? Que se venia la segunda ola ? La prensa (no toda ) miente, y el ministerio de salud también. Porqué no pasan la lista de los muertos de accidente de tránsito por dia ? o la lista de los que mueren por enfermedades olvidadas, o por tuberculosis misma ?
Y asi diarios cómo Clarin, se suman al terrorismo sanitario, tirando el número de muertos que el gobierno les dice. Porque de paso el ministerio no nos cuenta también la cantidad de síndromes de Guillain Barré que se han sucedido en estos años. Supuestamente si se han vacunado 4 millones cada uno de estos años, debieramos tener unos 40 casos de Guillain Barré, o es esta la vacuna perfecta contra la enfermedad más terrible ? Gripe y Calma.
He aquí el artículo:  http://www.clarin.com/salud/muertos-gripe-pais-afectados_0_935906445.html
Caso extraño, el mismo diario que aglutina a los opositores al gobierno, es casi siempre uno de los mejores voceros del Ministerio de Salud.
Este tipo de noticias en nada ayudan. Lo único que provocan es que la gente tema a vacunas que SI son necesarias. Y alguien del gobierno debiera controlar a un Ministerio que inició su ciclo justamente a mitad de la "pandemia". 
He aqui algunos datos de fines de mayo, del propio ministerio de salud de argentina, que de los otros virus que provocan sintomas gripales, no habla. No son muertos, son los virus que andan circulando.

Menores de 2 años (650 casos positivos de 5891 estudiados SE 1 a 21)

• VSR: 43,23 %
• Parainfluenza: 28,46 %
• Adenovirus: 15,08 %
• Metapneumovirus: 9,23 %
• Influenza A no tipificado 1,38 %
• Influenza B: 1,08%
• Influenza A H1N1: 0,92%
• Influenza A H3 estacional: 0,63%

De 2 a 64 años (239 casos positivos de 2718 estudiados SE 1 a 21)

• VSR: 21,34 %
• Influenza A H1N1: 17,99%
• Parainfluenza: 15,90%
• Adenovirus: 13,39%
• Influenza A no tipificado: 11,72%
• Influenza A H3 estacional. 9,62%
• Metapneumovirus: 5,44%
• Influenza B: 4,60%

En las últimas 6 semanas se han reportado 58 casos de Influenza de los cuales 56 

correspondieron al tipo A y sólo 2 al tipo B. Dentro del tipo A, se identificaron 36 como 

A H1N1 pdm y 6 como H3 Estacional......

Nota:

SE 21: (19 a 25 mayo)

SE 18: (28 abril al 4 mayo)

En cuanto a la efectividad de la vacuna en adultos puede leerse en http://medicina-general-familiar.blogspot.com.ar/2013/06/vaccines-to-prevent-influenza-in.html

Nota: agradecimiento a Mario Elmo en Pedamb ( Pediatria Ambulatoria )

Related articles

• Haiti: "Bird flu" leads to ban on Dominican eggs
• What is Influenza?
• Prominent virologist defends the Chinese Hybrid H5N1-H1N1 research, calls it 'good science'
• H1N1, H5N1, H7N9? What on earth does it all mean
• The Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccination: A Study of Maternal-Cord Blood Pairs in Taiwan
• Pandemic Influenza Viruses - Hoping for the Road Not Taken.
• New way to develop influenza A vaccine
• Risk Perception, Preventive Behaviors, and Vaccination Coverage in the Korean Population during the 2009 - 2010 Pandemic Influenza A (H1N1): Comparison between High-Risk Group and Non - High-Risk Group
• Racaniello: Influenza H5N1 x H1N1 reassortants: ignore the headlines, it's good science
• H7N9: From anxiety to preparedness

Natural inmunity against A/H1N1 2009 ( flu virus )

English: Swineflu cases in the UK (HPA modelling) (Photo credit: Wikipedia)

 In spite of many evidence support that the flu vaccine is not effective, this article focus also in the natural inmunity against the A/N1H1, where in cities like London the number climbs to 70% of the population who has natural antibodies against these virus. So, the question is......why the CDC and WHO persist in these kinds of policies, where the only who win something is Big Pharma ?

Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009.

Full Text

Hardelid P, Andrews NJ, Hoschler K, Stanford E, Baguelin M, Waight PA, Zambon M, Miller E.

Source

Centre for Infections, Health Protection Agency, London, UK.

Abstract

OBJECTIVES:

The objectives of the H1N1 2009 serological surveillance project were twofold: to document (1) the prevalence of cross-reactive antibodies to H1N1 2009 by age group in the population of England prior to arrival of the pandemic strain virus in the UK and (2) the age-specific incidence of infection by month as the pandemic progressed by measuring increases in the proportion of individuals with antibodies to H1N1 2009 by age.

METHODS:

Residual aliquots of samples submitted to 16 microbiology laboratories in eight regions in England in defined age groups in 2008 and stored by the Health Protection Agency serological surveillance programme were used to document age-stratified prevalence of antibodies to H1N1 2009 prior to the arrival of the pandemic in the UK. Functional antibodies to the H1N1 2009 virus were measured by haemagglutination inhibition (HI) and microneutralisation (MN) assays. For timely measurement of monthly incidence of infection with H1N1 2009 between August 2009 and April 2010, the microbiology serum collections were supplemented by collection of residual sera from chemical pathology laboratories in England. Monthly seroincidence samples were tested by HI only, apart from the final sera collected post pandemic in 2010, which were also tested by MN. Incidence during the pandemic was estimated from changes in prevalence between time points and also by a likelihood-based method.

SETTING:

Eight regions of England.

PARTICIPANTS:

Serum samples from patients accessing health care in England from whom blood samples were taken for unrelated microbiological or chemical pathology testing.

INTERVENTIONS:

None.

MAIN OUTCOME MEASURES:

Baseline age-specific prevalence of functional antibodies to the H1NI 2009 virus prior to the arrival of the pandemic; changes in antibody prevalence during the period August 2009 to April 2010.

RESULTS:

Pre-existing cross-reactive antibodies to H1N1 2009 were detected in the baseline sera and increased with age, particularly in those born before 1950. The prediction of immunological protection derived from the baseline serological analysis was consistent with the lower clinical attack rates in older age groups. The high levels of susceptibility in children < 15 years, together with their mixing within school, resulted in the highest attack rates in this age group. Serological analysis by region confirms that there were geographical differences in timing of major pandemic waves. London had a big first wave among the 5- to 14-year age group, with the rest of the country reducing the gap after the second wave. Cumulative incidence in London remained higher throughout the pandemic in each age group. By the end of the second wave it is estimated that as many as 70% of school-aged children in London had been infected. Taken together, these observations are consistent with observations from previous pandemics in 1918, 1957 and 1968 - that the major impact of influenza pandemics is on younger age groups, with a pattern of morbidity and mortality distinct from seasonal influenza epidemics.

CONCLUSIONS:

Serological analysis of appropriately structured, age-stratified and geographically representative samples can provide an immense amount of information to set in context other measures of pandemic impact in a population, and provide the most accurate measures of population exposure. National scale seroepidemiology studies require cross-agency coordination, multidisciplinary working, and considerable scientific resource.

FUNDING:

The National Institute for Health Research Health Technology Assessment programme and the Health Protection Agency.

Related articles

• Mutations in NA That Induced Low pH-Stability and Enhanced the Replication of Pandemic (H1N1) 2009 Influenza A Virus at an Early Stage of the Pandemic
• H1N1 discovered in marine mammals
• H1N1 discovered in marine mammals
• Broad Protection To Pandemic Flu Strains, Including 1918 Flu, Provided By Gene Therapy In Mouse Model
• Boosting Body's Natural Killers May Be The Way Forward For Fighting Flu
• 23andMe H1N1 Flu Survey: Share Your Experience
• Gene therapy gives mice broad protection to pandemic flu strains, including 1918 flu
• H1N1 swine flu virus discovered in marine mammals
• 'Nasal Spray' Vaccine Could Protect Against All Flu Strains
• H1N1 swine flu virus discovered in marine mammals

The perfect vaccine

Image via Wikipedia

Source: The Lancet, Volume 378, Issue 9802, Pages 1545 - 1546, 29 October 2011

Guillain-Barré syndrome and H1N1 influenza vaccine in UK childrendoi:10.1016/S0140-6736(11)61665-6Cite or Link Using DOI

Christopher Verity a, Lesley Stellitano a, Anne Marie Winstone a, Nick Andrews b, Julia Stowe b, Elizabeth Miller b

In 1976, the US National Influenza Immunization Programme (against swine influenza) was discontinued because of an increased risk of Guillain-Barré syndrome within 6 weeks of vaccination.1 Guillain-Barré syndrome surveillance was therefore imperative for pandemic H1N1 (swine) influenza vaccines and was fast-tracked for UK children younger than 17 years by use of the British Paediatric Surveillance Unit (BPSU) system. Fisher's syndrome is related to Guillain-Barré syndrome, so both disorders were included. Follow-up clinical questionnaires were sent to paediatricians who reported cases via the BPSU. Histories of H1N1 and seasonal influenza vaccination were obtained from general practitioners.

Between September, 2009, and August, 2010, 55 children developed symptoms of Guillain-Barré syndrome and two of Fisher's syndrome. Of these, 49 had clinical or laboratory evidence (or both) of an infection in the 3 months before the neurological symptoms started—22 had respiratory infections, 13 gastroenteritis, seven H1N1 influenza (five laboratory-confirmed), two seasonal influenza (one laboratory confirmed), two Epstein-Barr virus, one chickenpox, and two had unexplained fevers. Three children with Guillain-Barré syndrome had received H1N1 or seasonal influenza vaccines. One child had two H1N1 doses of a whole-virion unadjuvanted vaccine at 5 weeks and 10 days before onset—the only case with an interval potentially indicating a causal relation with Guillain-Barré syndrome.1 Another had received one dose of H1N1 vaccine 6 months before and the third a seasonal influenza vaccine 4 months before onset.

Between October, 2009, and March 31, 2010, an estimated 855 378 children in England received H1N1 vaccine,2 most with an AS03B adjuvanted split-virion vaccine. Additional children were vaccinated elsewhere in the UK (which our study covers). A single case of Guillain-Barré syndrome with onset within 6 weeks of H1N1 vaccination is what would be expected by chance in the vaccinated cohort given the background rate of Guillain-Barré syndrome in this age group.3

Of the 57 cases of Guillain-Barré syndrome or Fisher's syndrome, nine had influenza (six laboratory-confirmed). This finding is consistent with that of a recent study that found no association between Guillain-Barré syndrome and seasonal influenza vaccination but a 16-fold increased risk within 1 month of an influenza-like illness.4 The peak in the number of children with Guillain-Barré syndrome or Fisher's syndrome shortly after the peak of the second wave of H1N1 infection in November, 2009, might reflect this causal association (figure). Given the proven effectiveness of pandemic influenza vaccine used in UK children,5the vaccination programme might have had an overall protective effect against Guillain-Barré syndrome.

Figure Full-size image (30K) Download to PowerPoint

Children reported to our study who first developed symptoms of Guillain-Barré syndrome or Fisher's syndrome between September, 2009, and Aug 31, 2010

This study was funded by the UK Department of Health Policy Research Programme, grant numbers 019/0047 and 039/0031. The views expressed in this letter are those of the authors and not necessarily those of the Department of Health. We declare that we have no conflicts of interest.

References

1 Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976—1977. Am J Epidemiol 1979; 110: 105. PubMed

2 Sethi M, Pebody R. Pandemic H1N1 (swine) influenza vaccine uptake amongst patient groups in primary care in England 2009/2010.http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_121014.pdf.(accessed May 16, 2011).

3 Black S, Eskola J, Siegrist CA, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009; 374: 2115-2122. Summary | Full Text | PDF(113KB) |CrossRef | PubMed

4 Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenza-like illness using the United Kingdom General Practice Research Database. Am J Epidemiol 2009; 169: 382-388. CrossRef | PubMed

5 Andrews N, Waight P, Yung CF, Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 2011; 203: 32-39. CrossRef | PubMed

a PIND/GBS Research Group, Box 267, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK

b Health Protection Agency, London, UK

Related articles

• Flu Vaccine Safety and Efficacy (randi.org)
• Should you get a flu shot? (aleksandreia.wordpress.com)
• Flu Shot Only 59% Effective; Still Pushed Due to Fear Mongering? (connectwithwellness.wordpress.com)
• The 2 Most Potent Anti-Flu Strategies (lewrockwell.com)
• Why should some people never get the flu shot (wiki.answers.com)
• Mike Adams vs. the flu vaccine (scienceblogs.com)
• No substantial link between swine flu vaccine and Guillain-Barre syndrome, confirm experts (eurekalert.org)
• A Budget of Dumb Asses 2011 (livingstrongandhappy.blogspot.com)
• Little Risk of Guillain-Barré with H1N1 Flu Vaccine (webmd.com)

Un documento para tener en cuenta

Image via Wikipedia

Este articulo llego a mi mail, como cientos de mails recibidos sobre conspiraciones y negocios en la pandemia que la OMS declaró en Junio de 2009.  No abona teorias conspirativas, si no más bien sobre preguntas que nos hemos hecho muchas veces durante estos meses, y más aun, con la llegada del pico de la pandemia al hemisferio norte: porqué una de las pandemias más benignas de la historia, está costando millones de dolares a los gobiernos, y ha generado un pánico sin precedentes? No fue escrito en un sitio de salud, sino en uno más vinculado a economia y finanzas, y creemos vale la pena prestarle atención.
Lo pueden leer desde aqui. http://knol.google.com/k/ruben-roa/mr-flu-acusado-de-graves-conflictos-de/2lyuwoedvc3qb/6